Corona Remedies Limited
NSE: CORONA · Pharmaceuticals · sector
₹2,041.40NSE close 2026-10-26
Key numbers
Market cap₹12,485 cr
Price₹2,041.40
52w high / low₹2,292 / ₹1,337
P/E62.7xSector median 27.9x
P/B16.7xSector median 2.9x
Book value₹122.1
Dividend yield–Sector median 0.48%
ROE26.6%Sector median 11.7%
ROCE30.1%Sector median 12.3%
OPM20.1%Sector median 14.0%
Debt / equity0.19xSector median 0.16x
EV/EBITDA42.2xSector median 18.6x
Interest cover34.9x
Current ratio0.96x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹44 cr vs borrowings ₹143 cr (FY26): borrowings are higher by ₹99 cr.
- Operating profit covered interest 34.9x in the last 12 months.
- Other income was 6% of net profit in the last 12 months.
- No dividend in the last 1 financial years.
- Price ₹2,041.40 on 2026-10-26: -10.9% from the 52-week high, +52.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,197.20 · low ₹1,362.60
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 361 | 342 | 353 | 422 |
| EBITDA | 78 | 64 | 62 | 93 |
| OPM % | 21.7% | 18.7% | 17.6% | 22.0% |
| Other income | 2 | 2 | 4 | 3 |
| Net profit | 52 | 41 | 45 | 60 |
| EPS (₹) | 8.55 | 6.75 | 7.41 | 9.83 |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY26 | TTM |
|---|---|---|
| Revenue | 1,403 | 1,479 |
| EBITDA | 275 | 298 |
| Net profit | 185 | 199 |
| EPS (₹) | 30.27 | 32.54 |
| Dividend / share (₹) | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY26 |
|---|---|
| Shareholders' equity | 747 |
| Borrowings | 143 |
| Cash & equivalents | 44 |
| Total assets | 1,205 |
| Fixed assets | 291 |
| Capital work in progress | 143 |
| Investments | 0 |
| Receivables | 146 |
| Inventory | 125 |
| Payables | 147 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY26 |
|---|---|
| Cash from operations | 229 |
| Cash from investing | -256 |
| Cash from financing | 25 |
| Capex | 174 |
| Free cash flow | 55 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY26 |
|---|---|
| ROE % | 24.8% |
| ROCE % | 27.8% |
| Debtor days | 38 |
| Inventory days | 175 |
| Payable days | 206 |
| Cash conversion cycle (days) | 7 |
| Working capital days | -3 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 69.00% |
| FIIs | 4.21% |
| DIIs | 16.45% |
| of which Mutual funds | 16.06% |
| of which Insurance | 0.25% |
| Government | 0.00% |
| Public (non-institutions) | 10.34% |
| Quarter | Dec 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Promoters % | 69.00% | 69.00% | 69.00% | 69.00% | 69.00% |
| Promoter group | % |
|---|---|
| Nirav Kirtikumar Mehta | 22.00% |
| Ankurbhai K Mehta | 22.00% |
| Kirtikumar Laxmidas Mehta | 20.00% |
| Dipaben Niravkumar Mehta | 2.00% |
| Brinda Ankur Mehta | 2.00% |
| Minaxi Kirtikumar Mehta | 1.00% |
| Hetvi Nirav Mehta | 0.00% |
| Vanshaj Niravkumar Mehta | 0.00% |
| Jitendrakumar Champaklal Vora | 0.00% |
| Chandrika Jitendrakumar Vora | 0.00% |
| Nehal Devang Vora | 0.00% |
| Heti Darshan Kothari | 0.00% |
| Vishwa Ankur Mehta | 0.00% |
| Jainam Ankur Mehta | 0.00% |
| Subodhbhai Vrajlal Parikh | 0.00% |
| Public holders above 1% | % |
|---|---|
| Sepia Investments Limited | 8.62% |
| Invesco India Small CAP Fund | 5.26% |
| HDFC Trustee Company Limited-hdfc Flexi CAP Fund | 4.10% |
| SBI Retirement Benefit Fund- Conservative Plan | 3.57% |
21,098 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| CORONA | ₹12,485 cr | 62.7x | 16.7x | 26.6% | 30.1% | 20.1% | – | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-06-19 | Dividend | Dividend - Rs 10 Per Share |
Documents
- Annual report FY26
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Developing, Manufacturing and Marketing of pharmaceutical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | CORONA |
| BSE code | 544644 |
| ISIN | INE02ZQ01018 |
| Face value | ₹10.0 |
| Incorporated | 2004-08-27 |
| Website | https://www.coronaremedies.com |
| Plants (India / abroad) | 2 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.